Bone Marrow Transplantation Market Report 2026

The bone marrow transplantation market size has grown strongly in recent years. It will grow from $12.11 billion in 2025 to $12.72 billion in 2026 at a compound annual growth rate (CAGR) of 5.1%. The growth in the historic period can be attributed to rising prevalence of leukemia and lymphoma, increasing awareness of bone marrow transplantation, advancement in transplantation techniques, growth of hospital and clinical infrastructure, availability of donor registries.

The bone marrow transplantation market size is expected to see strong growth in the next few years. It will grow to $15.96 billion in 2030 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to emerging stem cell technologies, integration of ai in patient matching, expansion of precision medicine applications, development of post-transplant supportive therapies, growth of emerging markets healthcare infrastructure. Major trends in the forecast period include personalized conditioning regimens, stem cell source optimization, post-transplant care innovations, donor matching and registry expansion, minimally invasive harvesting techniques.

The increasing number of clinical trials focused on cell therapy is anticipated to drive the growth of bone marrow transplantation in the coming years. Clinical trials for cell therapy involve research studies conducted on human participants to assess the safety and effectiveness of using living cells to treat various diseases or medical conditions. These trials frequently rely on bone marrow transplantation because it provides hematopoietic stem cells, which are vital for replacing damaged cells, treating blood-related disorders, and supporting the development of innovative cell-based therapies for multiple diseases. For example, in December 2024, data from the Association of the British Pharmaceutical Industry, a UK-based trade association, showed that the number of pharmaceutical industry trials initiated in the UK rose for the second year in a row, increasing from 411 in 2022 to 426 in 2023. As a result, the rising volume of clinical trials for cell therapy is expected to fuel the bone marrow transplantation market.

Leading companies in the bone marrow transplantation sector are increasingly adopting strategic partnerships to improve access to advanced technologies, expand available treatment options, and deliver comprehensive transplant solutions. Strategic partnerships involve companies collaborating by combining their respective strengths and resources to achieve shared benefits and long-term success. For instance, in August 2023, Ossium Health, a US-based bioengineering firm, entered into a partnership with Be the Match BioTherapies, a US-based provider of cell and gene therapy solutions. Through this collaboration, the partners aim to enhance the accessibility of bone marrow transplants and improve treatment efficiency. This alliance significantly strengthens Ossium’s ability to serve a larger patient population, while allowing NMDP or Be The Match to provide a new source of bone marrow to a wider range of patients in need of life-saving therapies.

In October 2024, Werfen, a Spain-based medical diagnostics company, acquired Omixon Bioinformatics Ltd. for $25 million. This acquisition is intended to strengthen Werfen’s transplant diagnostics portfolio by improving precision and operational efficiency in bone marrow transplantation procedures, ultimately leading to better patient outcomes. Omixon Bioinformatics Ltd., based in Hungary, specializes in transplant diagnostics and offers genetic and immunological testing solutions designed to ensure compatibility in organ and bone marrow transplants.

Major companies operating in the bone marrow transplantation market are Merck Millipore Corporation, STEMCELL Technologies Inc., HemaCare Corporation, AllCells LLC, Lonza Group Ltd., Conversant Bio Company, Lifeline Cell Technology LLC, Mesoblast Ltd., PromoCell GmbH, ATCC Inc. (American Type Culture Collection), ReachBio LLC, Gamida Cell Ltd., Abbott Laboratories Inc., Allogene Therapeutics Inc., Amgen Inc., Angiocrine Biosciences Corp., Astellas Pharma Inc., Atara Biotherapeutics Inc., Bluebird Bio Inc., Cellectis S.A., Celyad SA, Erythrocyte Regeneration and Clinical Therapeutics Inc., Gammacell AB, Gilead Sciences Inc., Graphite Bio Inc., Incyte Corporation, Intellia Therapeutics Inc., Legend Biotech Corporation, Magenta Therapeutics Inc., Novartis AG.

North America was the largest region in the bone marrow transplantation market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global bone marrow transplantation market report forecast period. The regions covered in the bone marrow transplantation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bone marrow transplantation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the bone marrow transplantation market by increasing the cost of imported medical equipment, stem cell storage systems, and conditioning regimen drugs, particularly affecting regions in asia-pacific and europe. Autologous and allogenic transplant segments face higher operational expenses due to these tariffs. While costs have risen, tariffs have also encouraged local manufacturing of transplant-related tools and technologies, driving innovation and self-reliance within the market.

The bone marrow transplantation market research report is one of a series of new reports that provides bone marrow transplantation market statistics, including bone marrow transplantation industry global market size, regional shares, competitors with a bone marrow transplantation market share, detailed bone marrow transplantation market segments, market trends and opportunities, and any further data you may need to thrive in the bone marrow transplantation industry. This bone marrow transplantation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Bone marrow transplantation (BMT) is a specialized therapeutic procedure used for individuals affected by certain malignancies or other medical conditions, involving the replacement of diseased or damaged bone marrow with healthy cells. This treatment is commonly applied in managing blood cell disorders, including leukemia and lymphoma.

The primary forms of bone marrow transplantation include autologous bone marrow transplant and allogenic bone marrow transplant. An autologous bone marrow transplant is a clinical approach that helps restore stem cells that have been damaged due to radiation therapy or high-dose chemotherapy in patients. Its applications include conditions such as Hodgkin lymphoma, acute leukemia, multiple myeloma, solid tumors, non-Hodgkin lymphoma, and others, and these procedures are carried out in hospitals, multispecialty clinics, and ambulatory surgical centers.

The bone marrow transplantation market includes revenues earned by providing transplantation services syngeneic transplants, allogeneic transplants, autologous transplants, haploidentical transplants, non-myeloablative transplants, and umbilical cord blood transplants. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.